In Part 1 of this three-part series, experts in oncology care provide their preliminary thoughts on value-based agreements and whether there is opportunity for such agreements to function in the US oncology market today.
The discussion took place during the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2019; Chicago, IL) and was moderated by Omar Ali, BSc(Honors)Pharm, DipClinPharm, MRPharmS, ACPP, head of payers, Verpora (United Kingdom).
- Andrew Hertler, MD, FACP, chief medical officer, New Century Health;
- Dan Wygal, executive director of contract and channel strategy, AstraZeneca; and
- Daniel Vaena, MD, medical oncologist, West Cancer Center.